HopeStage
Back to all studies
CompletedNCT03826875

Preventing Depression After Aneurysmal Brain Bleeding

About this titleRead the official source — NCT03826875
Medication studyAges 18–85United States
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 85 years. Other eligibility criteria applied.

What did participation involve?

Depending on the group, the protocol specifies the study medication (fluoxetine) or a placebo (an inactive comparison treatment).

Listed locations
SeattleSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 1, 2019
Recruitment status
Completed
Enrollment listed in the registry
8
Sponsor
University of Washington
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 85 Years
Official registry ID
NCT03826875
Official title
Show the full official title

Preventative Treatment of Depression in Survivors of Aneurysmal Subarachnoid Hemorrhage

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Seattle

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Washington, a university.

Did this study involve medication?

Yes. The study involved medication, including Fluoxetine and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 85 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies